BGMA and MHRA come together for quality forum
The British Generic Manufacturers Association will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Tuesday, February 24th...
List view / Grid view
News
Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
16 January 2015 | By Roche
Roche announced that it has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France...
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
BIOTRONIK announces first enrollments in new study evaluating reduction of Thromboembolic events via GoldTip ablation
15 January 2015 | By BIOTRONIK
Trial to demonstrate efficacy of AlCath Flux eXtra gold ablation catheter in Reducing the incidence of harmful Thromboemboli...
Denmark’s pharmaceutical market value to decline to $3 billion by 2020, says GlobalData
14 January 2015 | By GlobalData
Denmark’s pharmaceutical market will decline in value from $3.5 billion in 2013 to $3 billion by 2020, with price-cap agreements and high tax rates on pharmaceutical products two of the largest barriers to growth, according to research and consulting firm GlobalData...
Novel Drug and Biosimilar launches to transform Rheumatoid Arthritis treatment market dynamics by 2023, says GlobalData
14 January 2015 | By GlobalData
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData...
Bristol-Myers Squibb and Lilly enter clinical collaboration agreement to evaluate Opdivo (nivolumab) in combination with Galunisertib in advanced solid tumors
14 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Eli Lilly and Company announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299)...
Dolomite’s microfluidics technology helping to advance antibody therapeutics
13 January 2015 | By kdm communications
Dolomite’s droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair™ technology...
Frost & Sullivan releases drug launch and Phase 3 trial watch list for top therapeutic areas
13 January 2015 | By Frost and Sullivan
Oncology, autoimmune and infectious diseases/vaccines are hot areas for novel therapeutics and in vitro diagnostics in 2015...
Director General of EFPIA: “Pan-European HTA necessary”
13 January 2015 | By eyeforpharma
Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma...
Perjecta (pertuzumab) and Kadcycla (trastuzumab emtansine) remain available through Cancer Drugs Fund, but Avastin (bevacizumab) denied
13 January 2015 | By Porter Novelli Limited
Roche welcomes the announcement from NHS England that patients can continue to access our breast cancer medicines Perjeta, Kadcyla and Avastin via the Cancer Drugs Fund (CDF), but is extremely disappointed that patients with advanced bowel and ovarian cancer will now be denied Avastin on the NHS, following their review…
Seattle Genetics and Bristol-Myers Squibb announce clinical collaboration to evaluate combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
12 January 2015 | By Bristol-Myers Squibb Company
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials...
CheckMate -017, a Phase 3 study of Opdivo (Nivolumab) compared to Docetaxel, stopped early
12 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC) was stopped early because an assessment conducted by the independent Data Monitoring Committee...
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
Global healthcare consulting market grows to over $6bn
8 January 2015 | By DWP Public Relations
Changing demographics, ever-evolving regulatory schemes, political pressure to cut costs and social pressure to improve care has led to strong growth in consulting to the global healthcare sector...
